RaySearch Laboratories Receives Largest RayStation Order to Date From Leading Austrian Particle Therapy Center
10/23/2012 9:22:27 AM
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: RaySearch Laboratories AB (STO:RAYB) has received an order for its RayStation® treatment planning system from MedAustron in Wiener Neustadt, Austria. MedAustron is an interdisciplinary national Austrian centre specializing in cancer treatment with ions, research and development of this new therapy and non-clinical research with ion and proton radiation. MedAustron is currently in the build-up phase and approximately 200 million Euros are being invested in this cutting-edge facility. After the center’s completion in 2015, up to 1400 patients will be treated annually using protons and carbon ion radiation. Ion beam therapy is the most advanced form of external radiotherapy where the tumor is irradiated with protons or carbon ions. Compared to conventional radiotherapy, where the tumor is irradiated with photons, the energy deposition of the ion beams can be controlled much more effectively. This means that the radiation dose can be delivered even more precisely and as a result, the unwanted dose to healthy tissues can be reduced, leading to a reduction of treatment-related side effects. In addition, radiation therapy with carbon ions can be used to target tumors with low levels of oxygen, so called hypoxic tumors, for which conventional radiation therapy has limited effect.
comments powered by